Favourable Long-Term Outcomes in Stage II/III TNBC With Atezolizumab Added to Chemotherapy, ctDNA Dynamics Provide Prognostic Value Beyond pCR By Ogkologos - July 28, 2025 635 0 Facebook Twitter Google+ Pinterest WhatsApp Final results from the IMpassion031 study Source RELATED ARTICLESMORE FROM AUTHOR Daraxonrasib Shows Antitumour Activity Among Patients with Previously Treated RAS-mutated Pancreatic Ductal Adenocarcinoma FDA Approves Vepdegestrant for ER-positive, HER2-negative, ESR1-mutated Advanced or Metastatic Breast Cancer Aiming to support a robust regulatory ecosystem for driving cancer research in Europe, ESMO provides feedback to the public consultation on dataset descriptions under... MOST POPULAR New Drugs Raise Old Questions about Treating Cancer during Pregnancy May 25, 2022 Woman Perfectly Breaks Down Grief Using ‘Ball In The Box’ Analogy... March 8, 2019 EMA Recommends Granting a Conditional Marketing Authorisation for Selpercatinib December 16, 2020 Comme louer son affaire en compagnie de tacht mahometane? (2023) August 13, 2023 Load more HOT NEWS FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy ΚΑΡΚΙΝΟΣ ΤΡΑΧΗΛΟΥ ΜΗΤΡΑΣ Our COVID-19 Response: How GreaterGood Is Making An Impact During The... After Losing His Mom To Breast Cancer, Man Founds ‘Not Just...
